Clinical Trials Logo

Clinical Trial Summary

OBJECTIVES: I. Determine the most sensitive outcome measures (functional or morphological) of a progressive renal injury in patients with IgA nephropathy.

II. Determine which of these patients are destined to progress to further injury in order to target them for therapy.

III. Elucidate the determinants of progression in those patients who exhibit evidence of either increasing impairment of ultrafiltration capacity or ongoing destruction of nephrons.


Clinical Trial Description

PROTOCOL OUTLINE: Patients receive oral enalapril daily. Treatment continues for 5 years in the absence of unacceptable toxicity.

Patients undergo renal function studies every 6-12 months for 5 years. Patients undergo renal biopsy at 36-48 months after study entry. ;


Study Design

Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00006137
Study type Interventional
Source Office of Rare Diseases (ORD)
Contact
Status Completed
Phase N/A
Start date May 2000

See also
  Status Clinical Trial Phase
Completed NCT00004448 - Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy Phase 2
Completed NCT01560052 - Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study) N/A
Completed NCT02527902 - Autonomic Nervous System (ANS) and Renal Function in Immunoglobin A (IgA) Nephropathy N/A
Completed NCT00004305 - Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis N/A
Completed NCT01115426 - Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis Phase 4